Blocking Bitterness

Drowning bitter-tasting pharmaceuticals in sweeteners or dispersing them into liposomes, microcapsules, or gums are standard ways to get people to swallow medications such as antibiotics, cold remedies, and ulcer medications. Cranbury, NJ-based Linguagen is developing a new approach using the signal transduction pathways that underlie taste: The company is screening libraries of small, natural molecules to be used as additives that would block the binding of bitter-tasting compounds before the b

Written byRicki Lewis
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Drowning bitter-tasting pharmaceuticals in sweeteners or dispersing them into liposomes, microcapsules, or gums are standard ways to get people to swallow medications such as antibiotics, cold remedies, and ulcer medications. Cranbury, NJ-based Linguagen is developing a new approach using the signal transduction pathways that underlie taste: The company is screening libraries of small, natural molecules to be used as additives that would block the binding of bitter-tasting compounds before the brain registers the unpleasant experience. According to a press release, regulatory clearance for the first of the company's blockers is anticipated "shortly."

Applications of altering ability to taste bitter chemicals are eclectic. "Agonizing a sweet receptor could amplify the perception of sweetness of nutritional sweeteners," says Shawn Marcell, CEO of Linguagen; such an application could reduce sugar content of a carbonated beverage by 90%. And blocking bitterness isn't restricted to making an antibiotic that a kid won't spit out. He ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies